[12] Patent
[11] Patent No.:GC0009379  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2018                56/2018  
Number of the Decision to Grant the Patent:2018/141739
Date of the Decision to Grant the Patent:17/Dec/2018

[21] Application No.:GC 2012-22610

[22] Filing Date:3/11/2012

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
2/11/2011
61/554,625

[72] Inventors:1- HUGHES, Adam D.،2- FENSTER, Erik،3- FLEURY, Melissa،4- GENDRON, Roland،5- MORAN , Edmund J

[73] Owner: Theravance Biopharma R&D IP, LLC, 901 Gateway, Boulevard, South San Francisco 94080, California , USA

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.7: [A61K31/165;A61K31/215; C07C231/02;C07C233/56;C07C241/04; C07C243/30;C07C271/22 ;C07D317/40]

[56] Cited Documents:

-US 2010305145 A1 (COPPOLA GARY MARK [US] ET AL) 2 December 2010
-JOURNAL OF MEDICINAL CHEMISTRY. AMERICAN CHEMICAL SOCIETY. US. vo 1 • 38. no. 10. 1 January 1995
-WO 2008083967 A2 (NOVARTIS AG [CH]; HOOK DAVID [CH]; RUCH THOMAS [CH]; RISS BERNHARD [FR) 17 July 2008
-WO 2009090251 A2 (NOVARTIS AG [CH]; HOOK DAVID [CH]; RISS BERNHARD [FR]; KAUFMANN DANIEL) 23 July 2009
-WO 2012112742 A1 (THERAVANCE INC [US]; FLEURY MELISSA [US]; GENDRON ROLAND [US]; HUGHES) 23 August 2012
-WO 2012082853 A1 (THERAVANCE INC [US]; GENDRON ROLAND [US]; FLEURY MELISSA [US]; HUGHES) 21 June 2012
 
Examiner: PH. Sultana K. AlOudah

[54] NEPRILYSIN INHIBITORS
[57] Abstract: In one aspect, the invention relates to compounds having the formula: (I)where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
No. of claims: 46


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.